Soligenix, Inc. Stock price
Is Soligenix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Soligenix, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Soligenix, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Soligenix, Inc. forecast:
Don't miss a Thing! We will send you all news about Soligenix, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Soligenix, Inc. Stock News
Company Profile
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
| Head office | United States |
| CEO | Dr. Schaber |
| Employees | 15 |
| Founded | 1987 |
| Website | www.soligenix.com |


